Jos Raats PhD
President and CEO
Jos established ModiQuest Research and its sister company, ModiQuest B.V focusing on the development of novel therapeutics for autoimmune diseases in 2004. He has been CEO of the ModiQuest group since 2004. Since 1994 he has worked in the recombinant antibody, and citrullination field studying citrullinated autoantigens, ACPA antibodies, and protein citrullination. He is co-inventor of the highly sensitive, gold standard, early diagnostic test for RA (anti-CCP test). He is co-inventor of the tACPA antibodies. He has managed numerous antibody lead generation programs within ModiQuest CRO branch. He has been involved in scientific research for more than 25 years, with over 50 publications from work at the University of Nijmegen, the Wellcome/CRC Institute in Cambridge (UK), at the University of Minnesota, in Minneapolis (USA), and ModiQuest.
Debby Kruijsen MSc PhD
Head Contract Research
Currently, Debby is responsible for all contract research projects within ModiQuest Research. She also directly supervises all hybridoma generation projects. Debby has been active in the field of cellular immunology and in vivo immunization and infection models since 2006. Her research work has focused on the role of antibodies in affecting antigen presentation and subsequent Respiratory Syncytial Virus specific T cell activation. The underlying mechanisms are critical for the development of effective vaccines.
As of 2014, Nienke is a member of the business development team of ModiQuest Research supporting client contract R&D projects. Previously, she was working as a researcher in the lab of ModiQuest Research focused on hybridoma generation and transient antibody productions. Nienke has a degree in biochemistry from HAN (Nijmegen, The Netherlands). If you have any questions or inquiries regarding ModiQuest’s custom antibody generation and development services, Nienke will be your first contact point.